Seminars in Oncology
Volume 34, Issue 4 , Pages 284-294 , August 2007

Detecting Early Pancreatic Cancer: Problems and Prospects

  • Suresh T. Chari

      Affiliations

    • Corresponding Author InformationAddress correspondence to Suresh T. Chari, MD, Mayo Clinic College of Medicine, Division of Gastroenterology and Hepatology, 200 First St SW, Rochester MN 55905.

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2007. CA Cancer J Clin. 2007;57:43–66
  2. Conlon KC, Klimstra DS, Brennan MF. Long-term survival after curative resection for pancreatic ductal adenocarcinoma (Clinicopathologic analysis of 5-year survivors). Ann Surg. 1996;223:273–279
  3. Maire F, Sauvanet A, Trivin F, et al. Staging of pancreatic head adenocarcinoma with spiral CT and endoscopic ultrasonography: An indirect evaluation of the usefulness of laparoscopy. Pancreatology. 2004;4:436–440
  4. Karmazanovsky G, Fedorov V, Kubyshkin V, et al. Pancreatic head cancer: Accuracy of CT in determination of resectability. Abdom Imaging. 2005;30:488–500
  5. Roche CJ, Hughes ML, Garvey CJ, et al. CT and pathologic assessment of prospective nodal staging in patients with ductal adenocarcinoma of the head of the pancreas. AJR Am J Roentgenol. 2003;180:475–480
  6. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg. 2000;4:567–579
  7. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200–1210
  8. Tsuchiya R, Noda T, Harada N, et al. Collective review of small carcinomas of the pancreas. Ann Surg. 1986;203:77–81
  9. Furukawa H, Okada S, Saisho H, et al. Clinicopathologic features of small pancreatic adenocarcinoma (A collective study). Cancer. 1996;78:986–990
  10. Shimizu Y, Yasui K, Matsueda K, et al. Small carcinoma of the pancreas is curable: New computed tomography finding, pathological study and postoperative results from a single institute. J Gastroenterol Hepatol. 2005;20:1591–1594
  11. Ishikawa O, Ohigashi H, Imaoka S, et al. Minute carcinoma of the pancreas measuring 1 cm or less in diameter—Collective review of Japanese case reports. Hepatogastroenterology. 1999;46:8–15
  12. Hruban RH, Goggins M, Parsons J, et al. Progression model for pancreatic cancer. Clin Cancer Res. 2000;6:2969–2972
  13. Adsay NV, Merati K, Andea A, et al. The dichotomy in the preinvasive neoplasia to invasive carcinoma sequence in the pancreas: Differential expression of MUC1 and MUC2 supports the existence of two separate pathways of carcinogenesis. Mod Pathol. 2002;15:1087–1095
  14. Brentnall TA, Bronner MP, Byrd DR, et al. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med. 1999;131:247–255
  15. Kimura W. How many millimeters do atypical epithelia of the pancreas spread intraductally before beginning to infiltrate?. Hepatogastroenterology. 2003;50:2218–2224
  16. Brat DJ, Lillemoe KD, Yeo CJ, et al. Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas. Am J Surg Pathol. 1998;22:163–169
  17. Brockie E, Anand A, Albores-Saavedra J. Progression of atypical ductal hyperplasia/carcinoma in situ of the pancreas to invasive adenocarcinoma. Ann Diagn Pathol. 1998;2:286–292
  18. Gangi S, Fletcher JG, Nathan MA, et al. Time interval between abnormalities seen on CT and the clinical diagnosis of pancreatic cancer: Retrospective review of CT scans obtained before diagnosis. AJR Am J Roentgenol. 2004;182:897–903
  19. Rulyak SJ, Kimmey MB, Veenstra DL, et al. Cost-effectiveness of pancreatic cancer screening in familial pancreatic cancer kindreds. Gastrointest Endosc. 2003;57:23–29
  20. Ghadirian P, Boyle P, Simard A, et al. Reported family aggregation of pancreatic cancer within a population-based case-control study in the Francophone community in Montreal, Canada. Int J Pancreatol. 1991;10:183–196
  21. Arnold MA, Goggins M. BRCA2 and predisposition to pancreatic and other cancers. Exp Rev Mol Med. 2001;3:1–10
  22. Goggins M, Schutte M, Lu J, et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res. 1996;56:5360–5364
  23. Ozcelik H, Schmocker B, Di Nicola N, et al. Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. Nat Genet. 1997;16:17–18
  24. Murphy KM, Brune KA, Griffin C, et al. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: Deleterious BRCA2 mutations in 17%. Cancer Res. 2002;62:3789–3793
  25. Hahn SA, Greenhalf B, Ellis I, et al. BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst. 2003;95:214–221
  26. Watson P, Lynch HT. Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer. 1993;71:677–685
  27. Bergman W, Watson P, de Jong J, et al. Systemic cancer and the FAMMM syndrome. Br J Cancer. 1990;61:932–936
  28. Goldstein AM, Fraser MC, Struewing JP, et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med. 1995;333:970–974
  29. Lowenfels AB, Maisonneuve P, Cavallini G, et al. International Pancreatitis Study Group Pancreatitis and the risk of pancreatic cancer. N Engl J Med. 1993;328:1433–1437
  30. Lowenfels AB, Maisonneuve P, Whitcomb DC International Hereditary Pancreatitis Study Group. Risk factors for cancer in hereditary pancreatitis. Med Clin North Am. 2000;84:565–573
  31. Lowenfels AB, Maisonneuve P, Whitcomb DC, et al. Cigarette smoking as a risk factor for pancreatic cancer in patients with hereditary pancreatitis. JAMA. 2001;286:169–170
  32. Klein AP, Brune KA, Petersen GM, et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res. 2004;64:2634–2638
  33. Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer (A meta- analysis). JAMA. 1995;273:1605–1609
  34. Ragozzino M, Jd Melton L, Chu CP, et al. Subsequent cancer risk in the incidence cohort of Rochester, Minnesota, residents with diabetes mellitus. J Chronic Dis. 1982;35:13–19
  35. Wideroff L, Gridley G, Mellemkjaer L, et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst. 1997;89:1360–1365
  36. Calle EE, Murphy TK, Rodriguez C, et al. Diabetes mellitus and pancreatic cancer mortality in a prospective cohort of United States adults. Cancer Causes Control. 1998;9:403–410
  37. Adami HO, McLaughlin J, Ekbom A, et al. Cancer risk in patients with diabetes mellitus. Cancer Causes Control. 1991;2:307–314
  38. Chow WH, Gridley G, Nyren O, et al. Risk of pancreatic cancer following diabetes mellitus: A nationwide cohort study in Sweden. J Natl Cancer Inst. 1995;87:930–931
  39. Noy A, Bilezikian JP. Clinical review 63: Diabetes and pancreatic cancer: Clues to the early diagnosis of pancreatic malignancy. J Clin Endocrinol Metab. 1994;79:1223–1231
  40. Gullo L, Pezzilli R, Morselli-Labate AM Italian Pancreatic Cancer Study Group. Diabetes and the risk of pancreatic cancer. N Engl J Med. 1994;331:81–84
  41. Cersosimo E, Pisters PW, Pesola G, et al. Insulin secretion and action in patients with pancreatic cancer. Cancer. 1991;67:486–493
  42. Permert J, Ihse I, Jorfeldt L, et al. Pancreatic cancer is associated with impaired glucose metabolism. Eur J Surg. 1993;159:101–107
  43. Permert J, Larsson J, Ihse I, et al. Diagnosis of pancreatic cancer (Alteration of glucose metabolism). Int J Pancreatol. 1991;9:113–117
  44. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997;20:1183–1197
  45. Chari ST, Klee GG, Miller LJ, et al. Islet amyloid polypeptide is not a satisfactory marker for detecting pancreatic cancer. Gastroenterology. 2001;121:640–645
  46. Permert J, Ihse I, Jorfeldt L, et al. Improved glucose metabolism after subtotal pancreatectomy for pancreatic cancer. Br J Surg. 1993;80:1047–1050
  47. Basso D, Brigato L, Veronesi A, et al. The pancreatic cancer cell line MIA PaCa2 produces one or more factors able to induce hyperglycemia in SCID mice. Anticancer Res. 1995;15:2585–2588
  48. Wang F, Larsson J, Abdiu A, et al. Dissociated secretion of islet amyloid polypeptide and insulin in serum-free culture media conditioned by human pancreatic adenocarcinoma cell lines. Int J Pancreatol. 1997;21:157–164
  49. Ding X, Flatt PR, Permert J, et al. Pancreatic cancer cells selectively stimulate islet beta cells to secrete amylin. Gastroenterology. 1998;114:130–138
  50. Ahren B, Andren-Sandberg A. Glucose tolerance and insulin secretion in experimental pancreatic cancer in the Syrian hamster. Res Exp Med. 1993;193:21–26
  51. Moossa AR, Levin B. Collaborative studies in the diagnosis of pancreatic cancer. Semin Oncol. 1979;6:298–308
  52. Jain M, Howe GR, St Louis P, et al. Coffee and alcohol as determinants of risk of pancreas cancer: A case-control study from Toronto. Int J Cancer. 1991;47:384–389
  53. Damiano J, Bordier L, Le Berre JP, et al. Should pancreas imaging be recommanded in patients over 50 years when diabetes is discovered because of acute symptoms?. Diabetes Metab. 2004;30:203–207
  54. Ogawa Y, Tanaka M, Inoue K, et al. A prospective pancreatographic study of the prevalence of pancreatic carcinoma in patients with diabetes mellitus. Cancer. 2002;94:2344–2349
  55. McNulty NJ, Francis IR, Platt JF, et al. Multi-detector row helical CT of the pancreas: effect of contrast-enhanced multiphasic imaging on enhancement of the pancreas, peripancreatic vasculature, and pancreatic adenocarcinoma. Radiology. 2001;220:97–102
  56. Johnson CD. Pancreatic carcinoma: Developing a protocol for multi-detector row CT. Radiology. 2001;220:3–4
  57. Tiitola M, Kivisaari L, Huuskonen MS, et al. Computed tomography screening for lung cancer in asbestos-exposed workers. Lung Cancer. 2002;35:17–22
  58. Diederich S, Wormanns D, Semik M, et al. Screening for early lung cancer with low-dose spiral CT: Prevalence in 817 asymptomatic smokers. Radiology. 2002;222:773–781
  59. Canto M, Wroblewski L, Goggins M, et al. Screening for pancreatic neoplasia in hgh-risk individuals: The Johns Hopkins experience. Gastroenterology. 2002;122(suppl 1):A-17
  60. Wiersema MJ, Vilmann P, Giovannini M, et al. Endosonography-guided fine-needle aspiration biopsy: Diagnostic accuracy and complication assessment. Gastroenterology. 1997;112:1087–1095
  61. Canto MI, Goggins M, Yeo CJ, et al. Screening for pancreatic neoplasia in high-risk individuals: An EUS-based approach. Clin Gastroenterol Hepatol. 2004;2:606–621
  62. Rajan E, Clain JE, Levy MJ, et al. Age-related changes in the pancreas identified by EUS: A prospective evaluation. Gastrointest Endosc. 2005;61:401–406
  63. Yusoff IF, Sahai AV. A prospective, quantitative assessment of the effect of ethanol and other variables on the endosonographic appearance of the pancreas. Clin Gastroenterol Hepatol. 2004;2:405–409

 Supported by grants from the National Institutes of Health (R01 CA 100685) and the Lustgarten Foundation.

PII: S0093-7754(07)00100-5

doi: 10.1053/j.seminoncol.2007.05.005

Seminars in Oncology
Volume 34, Issue 4 , Pages 284-294 , August 2007

Article Tools

* Image Usage & Resolution